We have developed a cytoplasmic replicating virus vector of Sendai virus (SeV) that infects and replicates in most mammalian cells, including neurons, and directs highlevel gene expression. To investigate the protective effect of SeV vector-mediated gene transfer of glial cell line-derived neurotrophic factor (GDNF) on the delayed neuronal death caused by transient global ischemia in gerbils, SeV vectors carrying either GDNF (SeV/ GDNF) or enhanced green fluorescent protein gene (SeV/GFP) were stereotaxically microinjected into the lateral ventricle. Four days after injection, occlusion of the bilateral common carotid arteries for 5 min produced transient global forebrain ischemia. Treatment with SeV/GDNF significantly decreased the delayed neuronal death of the hippocampal CA1 pyramidal neurons observed 6 days after the operation. TUNEL staining demonstrated that SeV/GDNF treatment markedly reduced the number of apoptotic cells in the hippocampal CA1 neurons, indicating that SeV/GDNF treatment prevented apoptosis. Furthermore, delayed neuronal death on the contralateral side of the hippocampal CA1 was also prevented to a similar extent as that on the ipsilateral side. These results suggest that SeV/GDNF prevents the delayed neuronal death induced by ischemia and is potentially useful for gene therapy for stroke.
Introduction
For use in the coming field of gene therapy, we have developed a novel gene transfer vector using Sendai virus (SeV), which is classified as a type I parainfluenza virus belonging to the family Paramyxoviridae with a negative-strand RNA genome [15, 24] . SeV is considered to be non-pathogenic to humans and has a strictly cytoplasmic life cycle in mammalian cells; i.e., its genomic RNA is restricted to the cytoplasm and has no interaction with the host chromosomes [15] . Therefore, SeV vector causes no genotoxicity and may in that regard be used safely in gene therapy for humans.
In addition, SeV vector shows potent infectivity in most mammalian cells including differentiated ones such as neuronal and muscular cells and directs high-level gene expression in these cells [17, 22, 27, 31] . Such advantageous characteristics of SeV vector in gene therapy prompted us to examine the therapeutical usefulness of the vector for diseases of the central nervous system (CNS).
Brain cells, especially neurons, are very fragile with respect to various types of injury such as ischemia, hypoxia and trauma. Mongolian gerbils (Meriones unguiculatus) are widely used as laboratory animals for the study of cerebral ischemia. Occlusion of the bilateral common carotid arteries of gerbils for 5 min causes transient forebrain ischemia, which results in the delayed neuronal death of the hippocampal CA1 pyramidal cells a few days after reperfusion. The pyramidal cells in the hippocampal CA1 region are well known to be the most vulnerable to cerebral ischemia [12, 13] , and this animal model is thought to reflect the pathological process in the cerebrovascular dementia of humans. Since cerebral ischemia also causes severe deficiency of memory function [3, 11, 16] , the prevention of delayed neuronal death by gene therapy has an enormous potential therapeutic value.
Glial cell line-derived neurotrophic factor (GDNF), a member of the transforming growth factor (TGF)-β superfamily [19] , is a potent neurotrophic factor that promotes survival and differentiation of dopaminergic neurons [4-6, 21, 28] and motoneurons [8, 18, 25] . It has been reported that the delayed neuronal death of the hippocampus CA1 region induced by transient global ischemia was prevented by administration of GDNF in rats [23] and gerbils [30] . However, direct injection of GDNF protein into patients has limited usefulness because of its poor bioavailability, its short half-life after administration, and also because producing suitable amounts of GDNF protein for clinical use is difficult. Therefore, a virus vector-mediated gene delivery system is expected to be an effective approach for local administration of these peptides into the brain.
In this study, we developed a novel SeV vector carrying the GDNF gene and examined whether the administration of this vector into the lateral ventricle could protect delayed neuronal death after transient global ischemia in gerbils.
Materials and Methods

Animals
Sixty-six adult male Mongolian gerbils (60-80 g) were used in this study. The animals were housed under controlled conditions of temperature (22 ± 2°C), humidity (50 ± 5%) and light/dark cycle (lights on from 6:00 to 18:00). Commercial food pellets and tap water were available ad libitum. The experimental protocol was approved by the Animal Care and Use Committee of the Graduate School of Agricultural and Life Sciences, the University of Tokyo.
Construction of Sendai virus vectors
Two recombinant Sendai virus vectors, Sendai virus carrying the mouse GDNF gene (SeV/GDNF) or enhanced green fluorescent protein gene (SeV/GFP), were constructed as previously described [7, 10, 17, 26, 27] . Briefly, the mouse GDNF cDNA was amplified with a pair of NotI-tagged (underlined) primers containing SeV-specific transcriptional regulatory signal sequences ( E n d a n d S t a r t , i t a l i c i z e d b e l o w ) , 5 ' -AGTTGCGGCCGCCAAAGTTCAATGAAGTTAT GGGATGTCGTGG-3' and 5'-ACGTGCGGCCGC GATGAACTTTCACCCTAAGTTTTTCTTACTACG GGGGTCAGATACATCCACACCGTTTAGCGG-3'. The amplified fragment was introduced into the NotI site of the parental pSeV18 + b(+), which was constructed to produce the exact SeV full-length antigenomic RNA of 15402 nucleotides, to generate pSeV18+mGDNF/ SeV. pSeV18+mGDNF/SeV was transfected to LLC-MK 2 cells that were infected with vaccinia virus vTF7-3, expressing T7 polymerase. The T7-driven full-length recombinant pSeV18+mGDNF/SeV RNA genomes were encapsulated by N, P and L proteins, which were derived from the respective cotransfected plasmids. After a 40-h incubation, a cell lysate of transfected cells was injected into embryonated chicken eggs to amplify the recovered virus and the virus titers were determined by a hemagglutination units (HAU) assay.
Injection of SeV vector into gerbil brain
For intraventricular injection of SeV vectors, animals were anesthetized by intraperitoneal injection of chloral hydrate (300 mg/kg) and positioned in a stereotaxic frame (David Kopf Instruments, USA), and an injection cannula was inserted to a position defined by the following stereotaxic coordinates: 1.0 mm posterior to the bregma, 1.0 mm lateral to the bregma, and 2.0 mm below the skull surface. The animals received a unilateral injection of either SeV/GDNF (5 µl, 1 × 10 9 p.f.u./ ml, n=8) or SeV/GFP (5 µl, 1 × 10 9 p.f.u./ml, n=8) using a 25-µl Hamilton syringe with a 30-gauge needle. After injection, the needle was left in place for 5 min and then it was slowly withdrawn from the brain to minimize the cerebrospinal fluid leakage.
Observation of GFP fluorescence after the injection of SeV/GFP
Four days after the injection of SeV/GFP (5 µl, 1 × 10 9 p.f.u./ml, n=6), the gerbils were sacrificed by ether anesthesia without transcardial perfusion. The brains were removed and sliced into coronal sections 300-µm-thick with a microslicer (DTK-1000; Dosaka, Japan). Expression of GFP protein was detected under a stereoscopic fluorescence microscope (Leica, Germany).
Quantification of GDNF protein in the hippocampus
SeV/GDNF (5 µl, 1 × 10 9 p.f.u./ml) or SeV/GFP (5 µl, 1 × 10 9 p.f.u./ml) was injected into the left lateral ventricle of gerbils (n=20 for each vector) and the gerbils were sacrificed without transcardial perfusion 1, 2, 4, 7 or 14 days after the injection. The brains were removed and the hippocampi dissected and homogenized with lysis buffer (20 mM Tris-buffered saline, pH 8.0, containing 0.1 M NaCl, 1% NP-40, 10% glycerol, 0.5 mM sodium vanadate, 1 mM PMSF, 10 µg/ml aprotinin and 1 µg/ml leupeptin). The homogenates were centrifuged at 15,000 g for 10 min at 4°C, and then the supernatants were collected as samples. An enzyme-linked immunosorbent assay for quantification of GDNF was performed according to the manufacturer's protocol (GDNF Emax Immunoassay Systems; Promega, Madison, WI, USA).
Transient common carotid artery occlusion
Four days after SeV vector injection, the gerbils were anesthetized by intraperitoneal injection of chloral hydrate (300 mg/kg), and then forebrain ischemia was induced by occlusion of the bilateral common carotid arteries for 5 min [20, 30] . The rectal temperature was measured using a thermocouple probe in the anus, and the body temperature was maintained at 37.5°C using a heating pad. Both common carotid arteries were clamped with surgical clips (Sugita aneurysm clips; Mizuho Ikakogyo, Tokyo, Japan), inducing transient forebrain ischemia. After 5 min of occlusion, the clips were removed to restore blood flow and the skin was sutured.
Immunohistochemistry
Six days after occlusion of the bilateral common carotid arteries, the gerbils were anesthetized with ether and perfused transcardially with normal saline followed by fixing using transcardiac perfusion with 4% paraformaldehyde in 0.1 M phosphate buffer (PB). The brains were removed and immersed in this fixative at 4°C overnight. Coronal brain sections were made from brains embedded in paraffin by cutting 5-µm and put on glass slides coated with 3-aminopropyl-triethoxysilane. For immunostaining of GFP, the paraffin sections were pretreated with 0.3% H 2 O 2 in PBS, followed by washing three times. After blocking with 10% normal goat serum (NGS) in PBS for 1 h, the sections were incubated overnight at 4°C with a rabbit polyclonal antibody to GFP (1:200, Molecular Probes, Eungene, OR, USA) in 3% NGS and 0.3% Triton X-100 in PBS. The sections were then washed and incubated for 1 h with biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA), followed by incubation for 1 h with the reagents for avidin biotin complex (Vector Laboratories). Immunopositive cells were visualized by 3,3'-diaminobenzidine tetrahydrochloride (DAB) (WAKO Pure Chmicals, Tokyo, Japan) and counterstained with hematoxylin.
Apoptosis assay
For detection of DNA fragmentation, terminal deoxynucleotidyl dUTP nick-end labeling (TUNEL) was performed using an Apoptag In Situ Apoptosis Detection kit according to the manufacturer's protocol (Intergen Company, Purchase, NY, USA). Briefly, paraffin sections were deparaffinized and incubated with 20 µg/ml proteinase K in PBS for 15 min, and incubated with digoxigenin-labeled dUTP in the presence of terminal deoxynucleotidyl transferase (TdT) in a humid atmosphere at 37°C for 1 h, then incubated with horseradish peroxidase (HRP)-conjugated antidigoxigenin antibody for 1 h at room temperature and stained with DAB. The sections were counterstained with hematoxylin.
Statistical analysis
The data are presented as mean ± s.d. Statistical analysis was performed using Student's t test. Statistical significance was determined at P<0.05.
Results
Infectivity of SeV vector in the gerbil brain
To examine the efficiency of SeV vector-mediated gene transfer into the brain, SeV/GFP was injected into the left lateral ventricle of gerbils. Four days after the intraventricular administration of SeV/GFP, GFP expression was observed under a stereoscopic fluorescence microscope. Intense GFP expression was observed around the ependymal layer of both lateral ventricles (Fig. 1a) and on both sides of the hippocampus (Fig.  1b, c) . The GFP intensities in the ependymal layer and hippocampi were slightly decreased 7 days after the injection relative to those 4 days after the injection (data not shown).
To identify the cells expressing SeV/GFP, immunostaining for GFP using anti-GFP antibody was performed. A GFP-positive reaction was observed in the ependymal cells of the lateral ventricles (Fig. 2a) , third ventricle (Fig. 2b) , hippocampi, cortex of Ammon's horn (Fig. 2c) , and choroid plexus (data not shown) at 4 days after the injection. However, the expression of GFP was not be detected in any of the cerebral cells, including the hippocampal CA1 pyramidal neurons. No GFP-positive cells were detected in the untreated gerbil brains.
Kinetics of GDNF amount after the injection of SeV/ GDNF
In order to evaluate the kinetics of the expression from the gene carrying SeV vector in the brain, the GDNF amount in the hippocampus of gerbils after the injection of SeV/GDNF was determined by an enzymelinked immunosorbent assay (ELISA). The amount of GDNF protein in the hippocampus was significantly increased after the injection of SeV/GDNF. GDNF protein could be detected even 1 day after the injection of SeV/GDNF (113.7 ± 6.1 pg/mg tissue). The level of GDNF protein reached a peak at 2341.7 ± 199.4 pg/mg tissue at 4 days after the injection of SeV/GDNF and then gradually decreased to 10.1 ± 1.2 pg/mg tissue at 14 days after injection. In contrast, a very small amount of GDNF protein was detected in gerbils treated with SeV/GFP. These results indicate that high-level expression of GDNF can be achieved by the injection of SeV/GDNF in the brain.
Protective effect of SeV/GDNF on delayed neuronal death of the hippocampal CA1 neurons
The protective effects of SeV/GDNF on the delayed neuronal death of the hippocampal CA1 neurons induced by occlusion of the carotid arteries in gerbils were examined. We assessed histopathological sections from gerbils treated with SeV/GDNF or SeV/GFP 6 days after transient global ischemia. In the animals injected with SeV/GFP, a marked degree of delayed neuronal death was observed in the CA1 regions on both sides of the hippocampi (Fig. 4b, 4d) . The injection of SeV/GDNF strongly prevented the delayed neuronal death in the hippocampal CA1 pyramidal neurons after transient global ischemia (Fig. 4a, 4c) . Pyknotic nuclei were observed in the SeV/GFP-treated group (Fig. 4d) , while surviving wheel-like nuclei were seen in the SeV/GDNF-treated group (Fig. 4c) . Furthermore, the neuroprotective effects of SeV/GDNF against delayed neuronal death were observed not only on the ipsilateral side where SeV/GDNF was injected, but also on the contralateral side of the hippocampal CA1 region (Fig. 5) .
For quantitative analysis, the number of surviving neurons along a 1-mm linear length of the hippocampal CA1 region was counted (Fig. 6) . The numbers of surviving neurons in the SeV/GFP group were only 12.4 ± 5.2 and 11.7 ± 5.1 cells/mm in the ipsilateral and contralateral sides of the hippocampal CA1 regions, respectively. In contrast, those in the SeV/GDNF group were 186.8 ± 8.1 and 170.3 ± 13.2 cells/mm in the ipsilateral and contralateral sides, respectively. The differences in the values between the groups were significant (P<0.01). These findings indicate that the administration of SeV/GDNF was effective at preventing the delayed neuronal death induced by transient global ischemia. served in the cases of SeV/GFP and SeV/GDNF (Fig.  7b) . These findings indicate that SeV/GDNF prevented apoptosis in CA1 neurons after transient ischemia.
Discussion
In the present study, we demonstrated that gene transfer and expression using the SeV vector system were very effective in the CNS and that the intraventricular administration of SeV/GDNF could prevent delayed neuronal death in the hippocampal CA1 pyramidal neurons induced by transient global ischemia.
Neurons are nonrepairable, postmitotic, highly differentiated cells that are extremely vulnerable to ischemic injury. Therefore, prevention of neuronal death is very important for reducing neurological deterioration in cerebrovascular or neurodegenerative diseases. The neuronal cell death induced by ischemic injury is a progressive process [1] . Therefore, the time course of the transgene expression is crucial for the effectiveness of gene therapy for ischemic injury. It is probable that the gene and protein expression directed by SeV vectors occurs very rapidly because of their rapid replication, high level of mRNA transcription and effective translation of the mRNA, the typical features of RNA viruses. These features suggest that SeV vectors are suitable for the treatment of cerebral ischemia.
Numerous studies have demonstrated that GDNF has protective effects against the loss of neurons induced by ischemic injury [2, 9, 14, 29] . However, the approaches used involved the topical application or the intraventricular administration of exogenous GDNF protein, and an extremely large amount of protein was necessary for preventing the neuronal loss. Moreover, the administration of neuroprotective agents such as GDNF protein has a critical limitation due to the presence of the blood-brain barrier, which makes the CNS relatively inaccessible to circulating proteins and peptides. These factors seem to be ineffective if they are not delivered by direct and repeated injections or con- 
The effect of SeV/GDNF administration against apoptosis
To examine whether SeV/GDNF effectively prevented apoptosis of the hippocampal CA1 pyramidal neurons of gerbils induced by transient global ischemia, TUNEL staining was carried out on sections from animals sacrificed 6 days after the ischemia. In the animals injected with SeV/GFP, a large number of TUNELpositive cells were observed in the hippocampal CA1 region (Fig. 7b, 7d ) on both the ipsi-and contralateral sides. On the other hand, in the hippocampal CA1 region of the animals treated with SeV/GDNF, few TUNEL-positive cells were detected (Fig. 7a, 7c ). There were few TUNEL-positive cells even among hippocampal CA1 neurons on the contralateral side of gerbils treated with SeV/GDNF (data not shown). In the other hippocampal regions such as CA3 and the dentate gyrus, no TUNEL-positive neurons were ob-tinuous infusion into the ventricle, striatum or cerebral cortex. In contrast, viral vectors direct the continuous expression of the genes they harbor. However, direct injection of viral vectors into the cerebral parenchyma is more invasive than intraventricular administration of viral vectors. Therefore, in this study we attempted a single intraventricular administration of SeV/GDNF in order to deliver the transferred GDNF gene product into the neighboring area effectively with minimal trauma and invasiveness.
After the administration of SeV/GFP into the lateral ventricle, the GFP-positive cells were restricted to the ependymal cells of the lateral and third ventricles and the choroid plexus, and did not include the hippocampal CA1 pyramidal cells. However, a large amount of GDNF protein was detected in the hippocampus by an ELISA assay when SeV/GDNF was administered. We consider it is likely that GDNF protein produced in the ependymal cells permeated to the cortex of hippocampus and CA1 pyramidal cells and caused the protective effect against delayed neuronal death. Our findings suggest that the secretion of gene products from transfected ependymal cells and the resultant effects of these secreted proteins on cerebral parenchyma cells could be a useful protein delivery system. Moreover, the neuroprotective effects were observed equally in the bilateral hippocampal CA1 neurons, indicating that the expressed proteins were extensively dispersed.
We demonstrated here that the administration of SeV/ GDNF 4 days before transient ischemia prevented the ischemia-induced delayed neuronal death. However, in practice gene therapy must be applied after the occurrence of a stroke in clinical application. Therefore, in further studies, the vector should be administered after occluding the bilateral carotid arteries. In addition, alternative routes of administration such as lumbar puncture may help to achieve the clinical trial for gene therapy.
In conclusion, this study demonstrated that SeV vector-mediated gene transfer of GDNF effectively prevented the delayed neuronal death of hippocampal CA1 pyramidal cells induced by the occlusion of the bilateral carotid arteries. These results indicate that gene therapy using SeV vector has great potential usefulness for the reduction of ischemic injury in the brain.
